SWS Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

SWS Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-18	Closed	-$7K	–	409
2017 Q4	$7K	Buy	+18	New	+$7.29K	0.01%	292

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

SWS Partners's REGN Position: Q1 2018 in Review

SWS Partners sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 18 shares — an estimated $7K sold.

SWS Partners first reported a position in REGN in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

SWS Partners reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
SWS Partners sold 18 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $7K.
SWS Partners first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 1 quarter.
SWS Partners's Regeneron Pharmaceuticals position peaked at $7K in Q4 2017.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on SWS Partners's 13F filing for Q1 2018, filed 15 May 2018.